Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 15 8:10 PM EDTNews

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (1893)5/11/2012 11:20:34 AM
From: bellweather  Read Replies (1) of 4474
Thanks Peter,

Still haven't had a chance to listen to the call(but expect it to be an encouraging experience when I do).

If Hs equal enthusiasm for EGFR is warranted(poor choice of words), short of ALK being a disappointment(highly unlikely), more positive surprises should be in the offing.

Personally, I wonder about how much of erlotinib's effectiveness is, despite the attendant side effects, due to it's role in inhibiting native EGFR-

To the degree that it is, 113s (single drug)EGFR performance, though involving less side effects, may be less efficacious than hoped for.

Are you aware of any updated data relating to this issue?

Re: Pona-Well, it just seems to be continuously onward and upward, and we haven't even seen any data(which should be forthcoming) on other tumor types!


Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.